Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,205 matching trials from the live ClinicalTrials.gov search.
Filters: "pulmonary hypertension" Clear all
Completed No phase listed Observational

Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset

NCT04729075
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
ARDS and COVID19 treatments
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

A Mobile Health Intervention in Pulmonary Arterial Hypertension

NCT03069716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions
Smartphone Text Messaging, Fitbit Charge HR
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 12, 2026, 1:48 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

NCT04062565
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Injectable Product, Riociguat Pill
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 12, 2026, 1:48 AM EDT
Terminated Phase 4 Interventional Results available

Treprostinil Combined With Tadalafil for Pulmonary Hypertension

NCT01302444
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Portland, Maine • Boston, Massachusetts • Newark, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 12, 2026, 1:48 AM EDT
Completed No phase listed Observational

Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH

NCT02631421
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Blood Sampling, Cardiac MRI
Procedure · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 12, 2026, 1:48 AM EDT
Terminated Phase 2 Interventional Results available

Macitentan in Pulmonary Hypertension of Sickle Cell Disease

NCT02651272
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Disease
Interventions
macitentan
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 12, 2026, 1:48 AM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

NCT03738150
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, SOC
Biological · Other
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Tucson, Arizona • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

NCT02932410
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Standard-of-care
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
1 Month to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 4 Interventional

Effectiveness and Cost Impact of a Telecommunications System in COPD

NCT00012805
View directory record Official record
Conditions
Lung Diseases, Obstructive
Interventions
Telephone Monitoring
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00325403
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Oral treprostinil (UT-15C) Sustained Release Tablets, Placebo
Drug · Other
Lead sponsor
United Therapeutics
Industry
Eligibility
12 Years to 75 Years
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

NCT01647945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
Drug
Lead sponsor
Edda Spiekerkoetter
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

NCT02279745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Oct 12, 2026, 1:48 AM EDT
Terminated No phase listed Observational

Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study

NCT04090866
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right-Sided Heart Failure
Interventions
PET/MRI
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 12, 2026, 1:48 AM EDT
Withdrawn Phase 2 Interventional

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure

NCT00598429
View directory record Official record
Conditions
Infant, Newborn, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn, Streptococcal Infections
Interventions
Inhaled Prostaglandin E1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
11
States / cities
Birmingham, Alabama • Palo Alto, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 4 Interventional Results available

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

NCT02191137
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Riociguat (Adempas, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
58
States / cities
Tucson, Arizona • La Jolla, California • Moreno Valley, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 12, 2026, 1:48 AM EDT
Terminated Phase 2 Interventional

An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

NCT00677872
View directory record Official record
Conditions
COPD, Pulmonary Hypertension
Interventions
PRX-08066
Drug
Lead sponsor
Epix Pharmaceuticals, Inc.
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Oct 12, 2026, 1:48 AM EDT
Terminated No phase listed Observational

Cardiovascular Implications of COVID-19

NCT04435457
View directory record Official record
Conditions
SARS-CoV 2, SARS Pneumonia, COVID-19, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Cardiac Complication
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Unmasking Right Ventricular and Pulmonary Derangements With Exercise and Oxygen in Early Stage Cardiopulmonary Diseases

NCT03911856
View directory record Official record
Conditions
Cardiopulmonary Disease
Interventions
Echocardiography, Pulmonary Gas Exchange
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 12, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)

NCT01966302
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
BPS-314d-MR
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 12, 2026, 1:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Smart Textile Sensor System for Health Monitoring

NCT05473702
View directory record Official record
Conditions
Heart Disease Chronic, Pulmonary Disease, Chronic Obstructive, Blood Pressure, Heart Rhythm Disorder
Interventions
Nanowear SimpleSense Wearable monitoring device
Device
Lead sponsor
Nanowear Inc.
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia • Brooklyn, New York • State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 12, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 12, 2026, 1:48 AM EDT
Active, not recruiting No phase listed Observational

Trans-pulmonary Biomarkers in Pulmonary Hypertension

NCT01961232
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 12, 2026, 1:48 AM EDT